Skip to main content

Table 6 The frequency of adverse events mild to moderate grades from day 1 to day 7 (related or not) after treatment initiation

From: Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial

  AS-SMP
3 days (A)
(N = 476)
AS-SMP
24 hours (B)
(N = 458)
AL
3 days (C)
(N = 450)
P-value
Vomiting – n (%) 22 (4.6) 32 (7.0) 10 (2.2) 0.003
Nausea-n (%) 15 (3.2) 19 (4.2) 14 (3.1) 0.6
Headache – n (%) 5 (1.1) 10 (2.2) 7 (1.6) 0.4
Weakness – n (%) 11 (2.3) 5 (1.1) 2 (0.4) 0.04
Anorexia – n (%) 16 (3.4) 11 (2.4) 17 (3.8) 0.5
Dizziness – n (%) 13 (2.7) 14 (3.1) 10 (2.2) 0.7
Diarrhea – n (%) 3 (0.6) 15 (3.3) 6 (1.3) 0.006
Rash – n (%) 3 (0.6) 5 (1.1) 1 (0.2) 0.3
Abdominal pain – n (%) 21 (4.4) 21 (4.6) 17 (3.8) 0.8
Others* – n (%) 15 (3.2) 10 (2.2) 12 (2.7) 0.7
Total – n (%) 124 (26.1) 142 (31.0) 96 (21.3) 0.004
  1. Data are no. (%) of participants with the sign or symptom from day 1 to day 7 after treatment
  2. * Others are: infections (skin, respiratory, intestinal...) pains...